Piramal Pharma Ltd News

Stocks to buy: Piramal Pharma, HSCL among 3 top bets by Choice Broking

Stocks to buy: Here's why Aakash Shah, technical analyst at Choice Broking recommends a 'Buy' on Piramal, Aza Engineering and Himadri Speciality Chemical this week.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

Piramal Pharma bets on FY27 rebound; expects mid-teens growth, margin gains

Piramal Pharma expects a recovery in FY27 with mid-teens revenue growth and improved margins, supported by CDMO rebound, stronger order inflows, and global supply chain shifts

Stocks to Watch today: Eternal, Ceat, Bandhan Bank, GRSE, Canara HSBC Life

Stocks to Watch today, April 29, 2026: Eternal, Ceat, Bandhan Bank, BHEL, Mobikwik, and Canara HSBC Life Insurance are some of the key stocks to watch today

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

Stocks to Watch today, Feb 16: Ola Electric, Kfin Tech, Inox Green, HUL

Stocks to Watch today, Feb 16: From Ola Electric to Inox Green Energy, here are few stocks that will be on investors' radar

USFDA issues Form 483 with 4 observations for Piramal Pharma's T'gana plant

Piramal Pharma has said the US health regulator has issued Form 483 with four observations after inspecting its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) conducted an inspection of the company's Digwal (Telangana ) based plant from February 9, 2026, to February 13, 2026. At the conclusion of the inspection, the USFDA issued a Form-483, with four observations, Piramal Pharma said in a regulatory filing on Friday. These observations are related to enhancement in procedures and not related to data integrity and indicated to be classified as a VAI (voluntary action indicated), it added. The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines, the drug maker stated. Piramal Pharma remains committed to maintaining the highest standards of compliance and will work closely with the agency to comprehensively address all the observations, it added. As per the USFDA, Form 48

Stocks to Watch today: Bharti Airtel, Hero MotoCorp, TMPV, LIC, MRF

Stocks to Watch today, February 6, 2026: PhysicsWallah, Mazagon Dock, JK Paper, Sai Life, SKF India, UltraTech Cement, and Federal Bank are among the top stocks to remain in focus today

Piramal Pharma flags early recovery signs in CDMO demand as Q3 loss widens

The company attributed the weaker performance largely to continued inventory destocking in one of its large on-patent commercial products, affecting its CDMO business

Piramal Pharma shares gain 4% on Q3 results; check key highlights inside

Following the results announcement, the company's share price rose 3.78 per cent to log an intraday high of ₹159.79 per share

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs